BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28903582)

  • 1. Methylprednisolone for prevention of ovarian hyperstimulation syndrome in patients with polycystic ovarian syndrome undergoing in-vitro fertilisation: a randomised controlled trial.
    Mohammadi Yeganeh L; Moini A; Shiva M; Mirghavam N; Bagheri Lankarani N
    J Obstet Gynaecol; 2018 Feb; 38(2):241-246. PubMed ID: 28903582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-vitro maturation versus IVF with GnRH antagonist for women with polycystic ovary syndrome: treatment outcome and rates of ovarian hyperstimulation syndrome.
    Das M; Son WY; Buckett W; Tulandi T; Holzer H
    Reprod Biomed Online; 2014 Nov; 29(5):545-51. PubMed ID: 25262236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study on clinical effect on infertility women with polycystic ovary syndrome treated by in vitro maturation and in vitro fertilization-embryo transfer].
    Yu R; Lin J; Zhao JZ; Wang PY; Xiao SQ; Zhang W
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):250-4. PubMed ID: 22781109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial.
    Palomba S; Falbo A; Carrillo L; Villani MT; Orio F; Russo T; Di Cello A; Cappiello F; Capasso S; Tolino A; Colao A; Mastrantonio P; La Sala GB; Zullo F; Cittadini E;
    Fertil Steril; 2011 Dec; 96(6):1384-1390.e4. PubMed ID: 21982727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration of methylprednisolone to prevent severe ovarian hyperstimulation syndrome in patients undergoing in vitro fertilization.
    Lainas T; Petsas G; Stavropoulou G; Alexopoulou E; Iliadis G; Minaretzis D
    Fertil Steril; 2002 Sep; 78(3):529-33. PubMed ID: 12215328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT).
    Lainas TG; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas GT; Alexopoulou E; Kolibianakis EM
    Hum Reprod; 2010 Mar; 25(3):683-9. PubMed ID: 20008886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of in vitro maturation of oocytes versus in vitro fertilisation in women with high antral follicle count: study protocol for a randomised controlled trial.
    Vuong LN; Ho VNA; Ho TM; Dang VQ; Phung TH; Giang NH; Le AH; Pham TD; Wang R; Norman RJ; Smitz J; Gilchrist RB; Mol BW
    BMJ Open; 2018 Dec; 8(12):e023413. PubMed ID: 30530584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follicular aspiration during the selection phase prevents severe ovarian hyperstimulation in patients with polycystic ovary syndrome who are undergoing in vitro fertilization.
    Zhu WJ; Li XM; Chen XM; Zhang L
    Eur J Obstet Gynecol Reprod Biol; 2005 Sep; 122(1):79-84. PubMed ID: 16154042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The administration of glucocorticoids for the prevention of ovarian hyperstimulation syndrome in in vitro fertilization: a prospective randomized study.
    Tan SL; Balen A; el Hussein E; Campbell S; Jacobs HS
    Fertil Steril; 1992 Aug; 58(2):378-83. PubMed ID: 1633906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of the efficiency between in-vitro maturation and in-vitro fertilization after early follicular phase GnRH agonist down-regulation in infertile women with polycystic ovary syndrome].
    Zhu RR; Xiao SQ; Zhao JZ; Lin J; Wang PY; Jin CC; Jin WM
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):833-7. PubMed ID: 24444560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?
    Shavit T; Ellenbogen A; Michaeli M; Kartchovsky E; Ruzov O; Shalom-Paz E
    Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():46-50. PubMed ID: 24965979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of the clinical outcomes of IVF-ET treatment in infertile patients with polycystic ovary syndrome or polycystic ovaries].
    Wang QL; Song J; Chen SL; Luo C; Chen X; Li M; Ni YP
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 May; 29(5):962-5. PubMed ID: 19460721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
    Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Research on the protocol of limited ovarian stimulation to prevent ovarian hyperstimulation syndrome].
    Zhu YM; Gao HJ; He RH; Huang HF
    Zhonghua Fu Chan Ke Za Zhi; 2006 Nov; 41(11):740-4. PubMed ID: 17327030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro maturation as an alternative to standard in vitro fertilization for patients diagnosed with polycystic ovaries: a comparative analysis of fresh, frozen and cumulative cycle outcomes.
    Walls ML; Hunter T; Ryan JP; Keelan JA; Nathan E; Hart RJ
    Hum Reprod; 2015 Jan; 30(1):88-96. PubMed ID: 25355587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nomogram Model to Predict the Probability of Ovarian Hyperstimulation Syndrome in the Treatment of Patients With Polycystic Ovary Syndrome.
    Li F; Chen Y; Niu A; He Y; Yan Y
    Front Endocrinol (Lausanne); 2021; 12():619059. PubMed ID: 34421814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevention of ovarian hyperstimulation syndrome.
    Corbett S; Shmorgun D; Claman P; ;
    J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.